Par Pharmaceutical will have to wait until 2032 to begin marketing a generic version of Omeros’ Omidria, according to a settlement the two companies agreed to after a 3-day trial.
Omeros sued Par after the latter company filed an abbreviated new drug application with the FDA in 2015 to market a generic version of Omidria (phenylephrine 1% and ketorolac 0.3% injection), a press release from Omeros said. The company claimed Par would infringe on its Orange Book-listed patents by marketing a generic version.
Under the terms of the settlement agreement, (Read more...)
Uncategorized